Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Quizartinib Indicated for the Treatment of FLT3-ITD AML

Drug Name

Quizartinib

Developer

Daiichi Sankyo

Therapy Class

FLT3 Inhibitor

Product Description

Selective FLT3 tyrosine kinase inhibitor

Current Indication

Acute myeloid leukaemia

Market Sector

Oncology

Development Status

Phase three
Expand

Go Top